Comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 vs 16p13 11 Microdeletion Syndrome C4304596
Clinical comparison between 3 Beta Hydroxysteroid Dehydrogenase Deficiency and 16p13 11 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
16p13 11 Microdeletion Syndrome C4304596
A rare chromosomal deletion where a portion of chromosome 16 is missing. It may be associated with developmental delays, intellectual disability, and sometimes congenital anomalies. Management focuses on supportive care and addressing individual needs.
6 comparison axes
Onset
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
16p13 11 Microdeletion Syndrome C4304596
0-null
Onset patterns differ
Severity
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
16p13 11 Microdeletion Syndrome C4304596
moderate
Different severity levels
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
16p13 11 Microdeletion Syndrome C4304596
Chronic
Differing course
Communicable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
16p13 11 Microdeletion Syndrome C4304596
No
Different transmission
Body System
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
16p13 11 Microdeletion Syndrome C4304596
congenital
Same/different system
Category
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
16p13 11 Microdeletion Syndrome C4304596
genetic
Different category
Bottom line
3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 and 16p13-11-microdeletion-syndrome-C4304596 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 16p13 11 Microdeletion Syndrome C4304596 | Discriminating power |
|---|---|---|---|
| Genital development | Ambiguous genitalia may occur from disordered sex-steroid synthesis. | Genital ambiguity is not a defining feature in the supplied description. | Moderate |
| Acute salt loss | Salt-wasting crisis is a recognized possible presentation. | Salt-wasting is not described as characteristic. | High |
| Neurodevelopment | Developmental delay is not established as a core feature. | Developmental delay and intellectual disability may occur. | Moderate |
When to favor each condition
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with ambiguous genitalia and suspected adrenal crisis
The endocrine disorder can impair adrenal hormone production and cause salt wasting.
High
Abnormal steroid profile suggesting a block in adrenal steroidogenesis
This points toward an enzyme deficiency rather than a chromosomal deletion.
Moderate
Need for long-term hormone replacement
Management may require replacement and monitoring, unlike primarily supportive genetic care.
Moderate
Choose 16p13 11 Microdeletion Syndrome C4304596 when
Developmental delay with possible congenital anomalies
The microdeletion may be associated with neurodevelopmental and structural findings.
Moderate
Chromosomal microarray shows a 16p13.11 deletion
A confirmed deletion supports this diagnosis over an adrenal enzyme disorder.
High
No biochemical evidence of adrenal steroid deficiency
Absence of endocrine crisis makes the chromosomal condition more plausible, but does not prove it.
Low
How key tests differ
| Test | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 16p13 11 Microdeletion Syndrome C4304596 | Interpretation |
|---|---|---|---|
| Adrenal steroid profile | May show disordered adrenal hormone production; exact cutoffs are not supplied. | No characteristic steroid abnormality is established. | An abnormal profile supports endocrine evaluation but is not itself a complete diagnosis. |
| Chromosomal microarray | Not expected to identify this enzyme deficiency. | May detect deletion of 16p13.11. | A deletion finding requires laboratory and clinical correlation. |
| Electrolytes during illness | Salt wasting may cause clinically important electrolyte disturbance. | No specific electrolyte pattern is established. | Results need urgent clinician interpretation and do not alone distinguish the conditions. |
Prognosis comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Potentially severe chronic endocrine disorder; survival and outcome data are not supplied.
- Factors
- Salt-wasting risk, hormone imbalance, and adequacy of monitoring may influence course.
16p13 11 Microdeletion Syndrome C4304596
- Outcome
- Often described as moderate, with variable developmental effects; exact outcomes are not established.
- Factors
- Extent of developmental delay, intellectual disability, and congenital anomalies may vary.
Time frame: Both are chronic; onset details are not established in the supplied axes.
Etiology, severity, available supportive or endocrine care, and individual findings affect outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | Possible, particularly with salt wasting. Not described as characteristic. Suspected crisis needs emergency care; exact risk is not established here. |
| Intellectual disability | Not established from the supplied description. May occur and varies among individuals. Severity and frequency are not quantified in the source data. |
| Congenital anomalies | Genital atypical development may occur. Congenital anomalies may sometimes be present. The pattern and extent require individual assessment. |
Patient education highlights
- HighUrgent symptoms
Seek emergency care for vomiting, lethargy, dehydration, or suspected salt-wasting crisis, especially in the endocrine disorder.
- MediumDiagnosis limits
An abnormal test or genetic finding needs specialist interpretation and does not by itself define prognosis.
- MediumCare planning
One condition may need hormone replacement and monitoring; the other generally needs individualized supportive care.